IIBR > Covid19 > Media

Media

Scientific publications

IIBR article is at Nature communication Top 50 read articles of 2020
IIBR's article: "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge" is at Nature communication Top 50 read articles of 2020
Clinical trials for IIBR's vaccine will begin on Sunday, November 1st
This is our vaccine's story from research to production
Introducing BriLife
"Bri", alludes to the Hebrew word for health, "briut,", "iL" alludes to Israel, and "life" speaks to the importance of the vaccine. The name of the institute, IIBR is also hidden there with pride.
Historic moment - IIBR's Covid-19 vaccine is underway
An important milestone was completed.
In a process that took place at IIBR, 25,000 dosages of the COVID-19 vaccine, intended to be used in the clinical trials, have been prepared.
Bottles, containing the vaccine, were filled with three batches (production series) in accordance to the needed dosages for the clinical trials.
The vaccine safety and efficacy were proven in preclinical studies at IIBR.

The vaccine awaits final regulatory stages of the Ministry of Health.

Picture was taken at IIBR
From strategies to tiger team
A glimpse to the story behind our article:

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
IIBR’s research and development progress for vaccine to Corona
Selected excerpts from IIBR’s Director General, Prof. Shmuel C. Shapira’s session to the Science and Technology Committee at The Knesset
IIBR set to begin human trials in vaccine against the coronavirus in autumn
“All of the successful preliminary trials offer very significant news and a great deal of hope” said Defense Minister Gantz. Director General of IIBR, Prof. Shapira: “There is an excellent vaccine, there are regulatory processes that the vaccine needs to go through. We will start safety and efficacy trials after the autumn holidays, but the product is in hand.”
A patent for 8 antibodies to the COVID 19 virus was submitted by The Israeli Institute for biological research
IIBR will continue to characterize these antibodies and others and a biological manufacture would be sought to mass produce it for clinical use.
New study shows that there is a low probability to be infected with Corona virus due to surface contact
A joint ongoing study led by IIBR researchers and physicians from Laniado and Assuta Ashdod hospitals tested the viability of corona virus in patient‘s environment surfaces. The study reveals low probability of being infected due to surface contact.
Israel Tests Coronavirus Vaccine Prototype on Rodents at Defense Lab
IIBR Director General, Professor Shmuel Shapira, informed Prime Minister Benjamin Netanyahu of "significant progress" in designing a vaccine prototype and that the institute "is now preparing a model for commencing an animal trial".
IIBR is assigned to produce a vaccine and antibody for the Novel Coronavirus
The Israel institute for biological research is assigned by the Israeli Prime mister, Mr. Benjamin Netanyahu, to produce a vaccine and antibody for the Novel Coronavirus.

Media

IIBR article is at Nature communication Top 50 read articles of 2020

Clinical trials for IIBR's vaccine will begin on Sunday, November 1st

Introducing BriLife

Historic moment - IIBR's Covid-19 vaccine is underway

From strategies to tiger team

IIBR’s research and development progress for vaccine to Corona

IIBR set to begin human trials in vaccine against the coronavirus in autumn

A patent for 8 antibodies to the COVID 19 virus was submitted by The Israeli Institute for biological research

New study shows that there is a low probability to be infected with Corona virus due to surface contact

Israel Tests Coronavirus Vaccine Prototype on Rodents at Defense Lab

IIBR is assigned to produce a vaccine and antibody for the Novel Coronavirus